Morgenstern C, Biermann E
Allgemeines Krankenhaus St. Georg. Hamburg, Germany.
Int J Clin Pharmacol Ther. 2002 May;40(5):188-97. doi: 10.5414/cpp40188.
The objective of the present study in 60 patients with chronic tinnitus aurium was to confirm the efficacy of oral treatment with 2 x 80 mg Ginkgo special extract EGb 761 per day subsequent to 10-day EGb 761 infusion treatment.
Patients with chronic tinnitus aurium underwent 10 days of in-patient infusion treatment with 200 mg/day EGb 761, after which they were randomized to double-blind, oral out-patient treatment with either 2 x 80 mg/day EGb 761 or placebo, given over a scheduled treatment period of 12 weeks. The primary outcome measure was the change in tinnitus volume in the more severely affected ear during randomized treatment.
Fifty-two of 60 patients (89.7%) completed the infusion treatment; complete sets of data were available for 40 (66.7%), 30 (50.0%) and 22 (36.7%) patients after 4, 8 and 12 weeks of randomized treatment, respectively. For the primary outcome measure, significant superiority of EGb 761 over placebo was demonstrated in the intention-to-treat analysis data set after 4, 8 and 12 weeks of out-patient treatment (p < 0.05, 1-tailed), although the absolute treatment group difference was moderate. The results were supported by the secondary outcome measures for efficacy (e.g. decreased hearing loss, improved self-assessment of subjective impairment). During out-patient treatment, there were no attributable adverse events under EGb 761.
A combination of infusion therapy followed by oral administration of Ginkgo special extract EGb 761 appears to be effective and safe in alleviating the symptoms associated with tinnitus aurium.
本研究针对60例慢性耳鸣患者,旨在确认在为期10天的银杏叶特殊提取物EGb 761静脉输注治疗后,每天口服2×80 mg EGb 761的治疗效果。
慢性耳鸣患者接受为期10天的住院静脉输注治疗,每天使用200 mg EGb 761,之后他们被随机分为两组,进行为期12周的双盲门诊口服治疗,一组服用2×80 mg/天的EGb 761,另一组服用安慰剂。主要观察指标是随机治疗期间受影响较严重耳朵的耳鸣音量变化。
60例患者中有52例(89.7%)完成了静脉输注治疗;随机治疗4周、8周和12周后,分别有40例(66.7%)、30例(50.0%)和22例(36.7%)患者有完整数据集。对于主要观察指标,在门诊治疗4周、8周和12周后的意向性分析数据集中,EGb 761在疗效上显著优于安慰剂(p<0.05,单尾检验),尽管治疗组间的绝对差异适中。疗效的次要观察指标也支持该结果(如听力损失减轻、主观障碍自我评估改善)。在门诊治疗期间,服用EGb 761未出现可归因的不良事件。
先进行静脉输注治疗,随后口服银杏叶特殊提取物EGb 761的联合治疗方法,在减轻与耳鸣相关的症状方面似乎有效且安全。